cliniphar Ltd. (JPX: 432A.T) Stock Competitors & Peer Comparison
See 432A.T's competitors and their performance on the JPX and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for 432A.T and its JPX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 432A.T | ¥1,450.00 | +0.00% | 1.5B | 7.62 | ¥190.24 | N/A |
| 4151.T | ¥2,256.00 | -0.29% | 1.2T | 14.52 | ¥155.37 | +2.97% |
| 3088.T | ¥2,529.00 | -1.02% | 994.7B | 17.78 | ¥142.22 | +1.98% |
| 3391.T | ¥2,161.50 | -2.64% | 979.4B | 16.80 | ¥128.64 | +2.17% |
| 3141.T | ¥3,160.00 | -2.86% | 656B | 34.25 | ¥92.27 | +1.29% |
| 3349.T | ¥6,436.00 | -3.12% | 510.1B | 15.92 | ¥404.34 | +1.27% |
| 7649.T | ¥1,235.50 | -2.75% | 459.7B | 7.29 | ¥169.42 | +2.02% |
| 9989.T | ¥3,629.00 | -2.08% | 424.5B | 13.52 | ¥268.36 | +3.61% |
| 3549.T | ¥4,000.00 | -2.44% | 379.9B | 22.29 | ¥179.42 | +1.40% |
| 3148.T | ¥3,300.00 | -1.49% | 213.2B | 12.45 | ¥265.09 | +2.82% |
Stock Comparison
Kyowa Kirin Co., Ltd. (JPX: 4151.T)
432A.T vs 4151.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 4151.T has a market cap of 1.2T. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 4151.T trades at ¥2,256.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 4151.T's P/E ratio is 14.52. In terms of profitability, 432A.T's ROE is N/A, compared to 4151.T's ROE of +0.09%. Regarding short-term risk, 432A.T is less volatile compared to 4151.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 4151.T's competition here
MatsukiyoCocokara & Co. (JPX: 3088.T)
432A.T vs 3088.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 3088.T has a market cap of 994.7B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 3088.T trades at ¥2,529.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 3088.T's P/E ratio is 17.78. In terms of profitability, 432A.T's ROE is N/A, compared to 3088.T's ROE of +0.11%. Regarding short-term risk, 432A.T is less volatile compared to 3088.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 3088.T's competition here
Tsuruha Holdings Inc. (JPX: 3391.T)
432A.T vs 3391.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 3391.T has a market cap of 979.4B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 3391.T trades at ¥2,161.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 3391.T's P/E ratio is 16.80. In terms of profitability, 432A.T's ROE is N/A, compared to 3391.T's ROE of +0.08%. Regarding short-term risk, 432A.T is less volatile compared to 3391.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 3391.T's competition here
Welcia Holdings Co., Ltd. (JPX: 3141.T)
432A.T vs 3141.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 3141.T has a market cap of 656B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 3141.T trades at ¥3,160.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 3141.T's P/E ratio is 34.25. In terms of profitability, 432A.T's ROE is N/A, compared to 3141.T's ROE of +0.06%. Regarding short-term risk, 432A.T is less volatile compared to 3141.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 3141.T's competition here
COSMOS Pharmaceutical Corporation (JPX: 3349.T)
432A.T vs 3349.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 3349.T has a market cap of 510.1B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 3349.T trades at ¥6,436.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 3349.T's P/E ratio is 15.92. In terms of profitability, 432A.T's ROE is N/A, compared to 3349.T's ROE of +0.12%. Regarding short-term risk, 432A.T is less volatile compared to 3349.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 3349.T's competition here
Sugi Holdings Co.,Ltd. (JPX: 7649.T)
432A.T vs 7649.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 7649.T has a market cap of 459.7B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 7649.T trades at ¥1,235.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 7649.T's P/E ratio is 7.29. In terms of profitability, 432A.T's ROE is N/A, compared to 7649.T's ROE of +0.11%. Regarding short-term risk, 432A.T is less volatile compared to 7649.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 7649.T's competition here
Sundrug Co.,Ltd. (JPX: 9989.T)
432A.T vs 9989.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 9989.T has a market cap of 424.5B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 9989.T trades at ¥3,629.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 9989.T's P/E ratio is 13.52. In terms of profitability, 432A.T's ROE is N/A, compared to 9989.T's ROE of +0.11%. Regarding short-term risk, 432A.T is less volatile compared to 9989.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 9989.T's competition here
Kusuri No Aoki Holdings Co., Ltd. (JPX: 3549.T)
432A.T vs 3549.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 3549.T has a market cap of 379.9B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 3549.T trades at ¥4,000.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 3549.T's P/E ratio is 22.29. In terms of profitability, 432A.T's ROE is N/A, compared to 3549.T's ROE of +0.12%. Regarding short-term risk, 432A.T is less volatile compared to 3549.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 3549.T's competition here
Create SD Holdings Co., Ltd. (JPX: 3148.T)
432A.T vs 3148.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 3148.T has a market cap of 213.2B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 3148.T trades at ¥3,300.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 3148.T's P/E ratio is 12.45. In terms of profitability, 432A.T's ROE is N/A, compared to 3148.T's ROE of +0.11%. Regarding short-term risk, 432A.T is less volatile compared to 3148.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 3148.T's competition here
Ain Holdings Inc. (JPX: 9627.T)
432A.T vs 9627.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 9627.T has a market cap of 194B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 9627.T trades at ¥5,519.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 9627.T's P/E ratio is 11.21. In terms of profitability, 432A.T's ROE is N/A, compared to 9627.T's ROE of +0.11%. Regarding short-term risk, 432A.T is less volatile compared to 9627.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 9627.T's competition here
NIHON CHOUZAI Co.,Ltd. (JPX: 3341.T)
432A.T vs 3341.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 3341.T has a market cap of 116.8B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 3341.T trades at ¥3,910.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 3341.T's P/E ratio is 45.91. In terms of profitability, 432A.T's ROE is N/A, compared to 3341.T's ROE of +0.03%. Regarding short-term risk, 432A.T is less volatile compared to 3341.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 3341.T's competition here
Genky DrugStores Co., Ltd. (JPX: 9267.T)
432A.T vs 9267.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 9267.T has a market cap of 105.8B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 9267.T trades at ¥3,470.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 9267.T's P/E ratio is 13.53. In terms of profitability, 432A.T's ROE is N/A, compared to 9267.T's ROE of +0.13%. Regarding short-term risk, 432A.T is less volatile compared to 9267.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 9267.T's competition here
Qol Holdings Co., Ltd. (JPX: 3034.T)
432A.T vs 3034.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 3034.T has a market cap of 88.3B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 3034.T trades at ¥2,349.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 3034.T's P/E ratio is 10.31. In terms of profitability, 432A.T's ROE is N/A, compared to 3034.T's ROE of +0.15%. Regarding short-term risk, 432A.T is less volatile compared to 3034.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 3034.T's competition here
Cawachi Limited (JPX: 2664.T)
432A.T vs 2664.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 2664.T has a market cap of 83.1B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 2664.T trades at ¥3,720.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 2664.T's P/E ratio is 25.99. In terms of profitability, 432A.T's ROE is N/A, compared to 2664.T's ROE of +0.03%. Regarding short-term risk, 432A.T is less volatile compared to 2664.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 2664.T's competition here
YAKUODO HOLDINGS Co., Ltd. (JPX: 7679.T)
432A.T vs 7679.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 7679.T has a market cap of 32.3B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 7679.T trades at ¥1,659.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 7679.T's P/E ratio is 8.25. In terms of profitability, 432A.T's ROE is N/A, compared to 7679.T's ROE of +0.10%. Regarding short-term risk, 432A.T is less volatile compared to 7679.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 7679.T's competition here
Astena Holdings Co., Ltd. (JPX: 8095.T)
432A.T vs 8095.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 8095.T has a market cap of 21.2B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 8095.T trades at ¥524.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 8095.T's P/E ratio is 9.13. In terms of profitability, 432A.T's ROE is N/A, compared to 8095.T's ROE of +0.08%. Regarding short-term risk, 432A.T is less volatile compared to 8095.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 8095.T's competition here
Satudora Holdings Co.,Ltd. (JPX: 3544.T)
432A.T vs 3544.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 3544.T has a market cap of 17.2B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 3544.T trades at ¥1,249.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 3544.T's P/E ratio is 101.84. In terms of profitability, 432A.T's ROE is N/A, compared to 3544.T's ROE of +0.04%. Regarding short-term risk, 432A.T is less volatile compared to 3544.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 3544.T's competition here
Renascience Inc. (JPX: 4889.T)
432A.T vs 4889.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 4889.T has a market cap of 16.4B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 4889.T trades at ¥1,193.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 4889.T's P/E ratio is -51.00. In terms of profitability, 432A.T's ROE is N/A, compared to 4889.T's ROE of -0.12%. Regarding short-term risk, 432A.T is less volatile compared to 4889.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 4889.T's competition here
Medical System Network Co., Ltd. (JPX: 4350.T)
432A.T vs 4350.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 4350.T has a market cap of 15.2B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 4350.T trades at ¥520.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 4350.T's P/E ratio is 17.52. In terms of profitability, 432A.T's ROE is N/A, compared to 4350.T's ROE of +0.05%. Regarding short-term risk, 432A.T is less volatile compared to 4350.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 4350.T's competition here
Ohki Healthcare Holdings Co.,Ltd. (JPX: 3417.T)
432A.T vs 3417.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 3417.T has a market cap of 13.8B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 3417.T trades at ¥1,014.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 3417.T's P/E ratio is 18.43. In terms of profitability, 432A.T's ROE is N/A, compared to 3417.T's ROE of +0.02%. Regarding short-term risk, 432A.T is less volatile compared to 3417.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 3417.T's competition here
KAINOS Laboratories, Inc. (JPX: 4556.T)
432A.T vs 4556.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 4556.T has a market cap of 10.1B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 4556.T trades at ¥2,268.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 4556.T's P/E ratio is 21.37. In terms of profitability, 432A.T's ROE is N/A, compared to 4556.T's ROE of +0.06%. Regarding short-term risk, 432A.T is similarly volatile compared to 4556.T. This indicates similar risk in terms of short-term price fluctuations for 432A.T.Check 4556.T's competition here
Pharmarise Holdings Corporation (JPX: 2796.T)
432A.T vs 2796.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 2796.T has a market cap of 5.7B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 2796.T trades at ¥499.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 2796.T's P/E ratio is 58.74. In terms of profitability, 432A.T's ROE is N/A, compared to 2796.T's ROE of +0.01%. Regarding short-term risk, 432A.T is less volatile compared to 2796.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 2796.T's competition here
Muromachi Chemicals Inc. (JPX: 4885.T)
432A.T vs 4885.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 4885.T has a market cap of 3.5B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 4885.T trades at ¥870.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 4885.T's P/E ratio is 21.44. In terms of profitability, 432A.T's ROE is N/A, compared to 4885.T's ROE of +0.06%. Regarding short-term risk, 432A.T is less volatile compared to 4885.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 4885.T's competition here
Miahelsa Holdings Corporation (JPX: 7129.T)
432A.T vs 7129.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 7129.T has a market cap of 3.3B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 7129.T trades at ¥1,170.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 7129.T's P/E ratio is 63.78. In terms of profitability, 432A.T's ROE is N/A, compared to 7129.T's ROE of +0.05%. Regarding short-term risk, 432A.T is less volatile compared to 7129.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 7129.T's competition here
SymBio Pharmaceuticals Limited (JPX: 4582.T)
432A.T vs 4582.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 4582.T has a market cap of 3B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 4582.T trades at ¥55.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 4582.T's P/E ratio is -0.57. In terms of profitability, 432A.T's ROE is N/A, compared to 4582.T's ROE of -9.37%. Regarding short-term risk, 432A.T is less volatile compared to 4582.T. This indicates lower risk in terms of short-term price fluctuations for 432A.T.Check 4582.T's competition here
COSMOS CHOUZAI Pharmacy Co.,Ltd. (JPX: 309A.T)
432A.T vs 309A.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 309A.T has a market cap of 2.1B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 309A.T trades at ¥700.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 309A.T's P/E ratio is 78.12. In terms of profitability, 432A.T's ROE is N/A, compared to 309A.T's ROE of N/A. Regarding short-term risk, 432A.T is similarly volatile compared to 309A.T. This indicates similar risk in terms of short-term price fluctuations for 432A.T.Check 309A.T's competition here
F&F Inc. (JPX: 357A.T)
432A.T vs 357A.T Comparison September 2026
cliniphar Ltd. (JPX: 432A.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 432A.T stands at 1.5B. In comparison, 357A.T has a market cap of 1.9B. Regarding current trading prices, 432A.T is priced at ¥1,450.00 on the JPX, while 357A.T trades at ¥6,240.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
432A.T currently has a P/E ratio of 7.62, whereas 357A.T's P/E ratio is 23.36. In terms of profitability, 432A.T's ROE is N/A, compared to 357A.T's ROE of N/A. Regarding short-term risk, 432A.T is similarly volatile compared to 357A.T. This indicates similar risk in terms of short-term price fluctuations for 432A.T.Check 357A.T's competition here